Flyer

Journal of Neurology and Neuroscience

  • ISSN: 2171-6625
  • Journal h-index: 15
  • Journal CiteScore: 2.13
  • Journal Impact Factor: 1.45
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Scientific Journal Impact Factor (SJIF)
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Abstract

New therapeutic strategies for Alzheimer’s disease

Mayank Jain*

Alzheimer's disease (AD) is an ever-evolving decay of cerebrum capability, at first portrayed by mental shortages, with loss of ongoing memory and language capacity, disability of direction, critical thinking, and unique reasoning. While existing medication medicines assist with diminishing the side effects of AD and work on individuals' personal satisfaction, they neither sluggish its movement nor fix it. As of now, designated drug conveyance to the focal sensory system (CNS), for treatment of AD, is bound by the difficulties presented by blood-mind interfaces encompassing the CNS, restricting the bioavailability of therapeutics. Among new systems to defeat these impediments and effectively convey medications to the CNS, nanoparticles (NPs) can beat these constraints, offering new helpful assignments in term of driving medications to cross the BBB and enter the cerebrum all the more really. The ebb and flow article expected to rundown and feature progresses in late examination on the improvement of nanotechnology-based therapeutics for their suggestions in treatment of AD.

Published Date: 2022-06-30; Received Date: 2022-05-19